V Recommandation pour l'utilisation d'urgence (Procédure EUL) du nouveau Vaccin Antipoliomyélitique Oral de Type 2 (nVPO2) de PT Biofarma (Persero) (Traduction de la version anglaise publiée le 01 Décembre 2020) PDF
V Recommendation for an Emergency Use Listing (EUL) of Novel Oral Polio Vaccine Type 2 (nOPV2) submitted by PT BioFarma (Persero) - (Published 01 December 2020) PDF
V Recommendation for an Emergency Use Listing (EUL) of Tozinameran (COVID-19mRNA Vaccine (Nucleoside Modified)) submitted by BioNTech Manufacturing GmbH PDF
V Recommendation for an Emergency Use Listing of COVID-19 mRNA Vaccine (nucleoside modified) submitted by Moderna Biotech (Spain) PDF
V Recommendation for an Emergency Use Listing of COVID-19 Vaccine Janssen Submitted by Janssen – Cilag International N. V. (Belgium) PDF
V Recommendation for an Emergency Use Listing of SKYCovione (COVID-19 Vaccine) Submitted by SK BIOSCIENCE Co Ltd PDF
V Roadmap for introduction and roll-out of Janssen VAC52150 (Ad26.ZEBOV, MVA-BN®-Filo) Ebola Virus Disease vaccine in African countries PDF
V Roadmap for introduction and roll‐out of Merck rVSV‐ZEBOV Ebola Virus Disease vaccine in African countries PDF